DKK 2016 | Precision medicine for lymphoma: Defining the individual patient

Lorenz Trümper

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from University Hospital of Göttingen, Göttingen, Germany, reviews the development of more tailored approaches for the treatment of lymphoma that have improved outcomes in patients.

Share this video  
Related videos
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
Waldenström’s macroglobulinemia: a link between institution visited and survival
Stephen Ansell
5:27
Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?
Miguel-Angel Perales
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
DKK 2016
Interview
25th February 2016
More from Lorenz Trümper
Treatment of lymphoma: Overview of the continued progress
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals